{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:32:32Z","timestamp":1790742752661,"version":"4.1.0"},"reference-count":94,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biotechnology Journal"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Established animal cells, such as Vero, Madin Darby canine kidney (MDCK) or chicken embryo fibroblasts (CEFs), are still the main cell lines used for viral vaccine production, although new \u201cdesigner cells\u201d have been available for some years. These designer cell lines were specifically developed as a cell substrate for one application and are well characterized. Later screening for other possible applications widened the product range. These cells grow in suspension in chemically defined media under controlled conditions and can be used for up to 100 passages. Scale\u2010up is easier and current process options allow cultivation in disposable bioreactors at cell concentrations higher than 1\u00d710\n                    <jats:sup>7<\/jats:sup>\n                    cells\/mL. This review covers the limitations of established cell lines and discusses the requirements and screening options for new host cells. Currently available designer cells for viral vaccine production (PER.C6, CAP, AGE1.CR, EB66 cells), together with other new cell lines (PBS\u20101, QOR\/2E11, SogE, MFF\u20108C1 cells) that were recently described as possible cell substrates are presented. Using current process knowledge and cell line development tools, future upstream processing could resemble today's Chinese hamster ovary (CHO) cell processes for monoclonal antibody production: small scale bioreactors (disposable) in perfusion or fed\u2010batch mode with cell concentrations above 1\u00d710\n                    <jats:sup>8<\/jats:sup>\n                    cells\/mL.\n                  <\/jats:p>","DOI":"10.1002\/biot.201400388","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T07:07:20Z","timestamp":1429686440000},"page":"728-740","source":"Crossref","is-referenced-by-count":119,"title":["Designing cell lines for viral vaccine production: Where do we stand?"],"prefix":"10.1002","volume":"10","author":[{"given":"Yvonne","family":"Genzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,22]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"crossref","unstructured":"Merten O.\u2010W. Bakker W. A. M. Vorlop J. Reiter M. et al. Virus production under suspension conditions in: Meyer H.\u2010P. Schmidhalter D. R. (Eds.) Industrial scale suspension culture of living cells Wiley Blackwell 2014 pp. 503\u2013554.","DOI":"10.1002\/9783527683321.ch14"},{"key":"e_1_2_11_3_2","first-page":"251","article-title":"Genetic aspects of cell line development from a synthetic biology perspective.","volume":"127","author":"Botezatu L.","year":"2012","journal-title":"Adv. Biochem. Eng. Biotechnol."},{"key":"e_1_2_11_4_2","doi-asserted-by":"crossref","unstructured":"Alldread R. M. Birch J. R. Metcalfe H. K. Farid S. et al. Large scale suspension culture of mammalian cells in: Meyer H.\u2010P. Schmidhalter D. R. (Eds.) Industrial scale suspension culture of living cells Wiley Blackwell 2014 pp. 411\u2013462.","DOI":"10.1002\/9783527683321.ch12"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/07388559009068265"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2009.08.019"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-36-1-59"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1997.8597"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.01-0995fje"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.4149\/av_2013_02_91"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.11.041"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2012.11.006"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.11.066"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1998.9.13-1909"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.10.161"},{"key":"e_1_2_11_16_2","unstructured":"Groener A. Vorlop J. Animal cells and processes for the replication of influenza viruses. WO Patent 9737000 1997."},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.06.045"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00024-13"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.02.015"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13337-012-0089-9"},{"key":"e_1_2_11_21_2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.14712\/fb2002048040126","article-title":"Chicken cells\u2010oncogene transformation, immortalization and more.","volume":"48","author":"Plachy J.","year":"2002","journal-title":"Folia Biol. (Praha)"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061530"},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-420118-7.00014-7"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2012.04.023"},{"key":"e_1_2_11_25_2","first-page":"143","article-title":"Human cells and cell cultures: availability, authentication and future prospects.","volume":"9","author":"Hay R. J.","year":"1996","journal-title":"Hum. Cell"},{"key":"e_1_2_11_26_2","first-page":"36","article-title":"Immortalization and malignant transformation of eukaryotic cells.","volume":"46","author":"Stepanenko A. A.","year":"2012","journal-title":"Tsitol Genet."},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-1702(93)90001-4"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1996.270.1.C1"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2013-0158"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2008.09.034"},{"key":"e_1_2_11_31_2","unstructured":"Kraus B. von Fircks S. Feigl S. Koch S. M. et al. 22nd European Society for Animal Cell Technology (ESACT) Meeting on Cell Based Technologies BMC Proceedings Vienna 2011."},{"key":"e_1_2_11_32_2","first-page":"141","article-title":"Establishment and characterization of a virus\u2010free chick cell line.","volume":"41","author":"Ogura H.","year":"1987","journal-title":"Acta Med. Okayama"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.08.122"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-3-3"},{"key":"e_1_2_11_35_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/978-1-62703-733-4_23","article-title":"Vaccine production: Upstream processing with adherent or suspension cell lines.","volume":"1104","author":"Genzel Y.","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"e_1_2_11_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.02.016"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201000292"},{"key":"e_1_2_11_38_2","doi-asserted-by":"publisher","DOI":"10.1385\/MB:15:3:249"},{"key":"e_1_2_11_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/v5010321"},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.09.037"},{"key":"e_1_2_11_41_2","unstructured":"Sandig V. Jordan I. Cell Line for Propagation of Highly Attenuated AlphaViruses.US Patent 229969 A1 2011."},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-014-5933-y"},{"key":"e_1_2_11_43_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072288"},{"key":"e_1_2_11_44_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1996.7.2-215"},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00508-9"},{"key":"e_1_2_11_46_2","first-page":"165","article-title":"Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines.","volume":"123","author":"Lewis J. A.","year":"2006","journal-title":"Dev. biol."},{"key":"e_1_2_11_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2012.01.008"},{"key":"e_1_2_11_48_2","unstructured":"Verschuur M. Yallop C. A. Meijer J. Scalable process for culturing PER.C6 cells and producing products therefrom.WO Patent 006989 A1 2010."},{"key":"e_1_2_11_49_2","doi-asserted-by":"publisher","DOI":"10.1021\/bp070258u"},{"key":"e_1_2_11_50_2","doi-asserted-by":"crossref","unstructured":"Yallop C. Crowley J. Cote J. Hegmans\u2010Brouwer K. et al. PER.C6 cells for the manufacture of biopharmaceutical proteins in: Kn\u00e4blein J. (Ed.) Modern biopharmaceuticals \/ 3. Weinheim: Wiley\u2010VCH 2005.","DOI":"10.1002\/9783527620982.ch33"},{"key":"e_1_2_11_51_2","unstructured":"Luitjens A. Herman Van H. Method for the production of ad26 adenoviral vectors. WO Patent 098592 A1 2011."},{"key":"e_1_2_11_52_2","doi-asserted-by":"publisher","DOI":"10.1089\/104303400750001417"},{"key":"e_1_2_11_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-012-4238-2"},{"key":"e_1_2_11_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2013.04.020"},{"key":"e_1_2_11_55_2","unstructured":"Sandig V. Jordan I. Brundke E. Productivity augmenting protein factor novel cell lines and uses thereof. US Patent 164727 A1 2012."},{"key":"e_1_2_11_56_2","unstructured":"Jordan I. Sandig V. Specific and persistent activation of heat shock response in cell lines using a viral factor. WO Patent 078928 A2 2010."},{"key":"e_1_2_11_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2010.11.005"},{"key":"e_1_2_11_58_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-14-72"},{"key":"e_1_2_11_59_2","first-page":"419","article-title":"The Avian EB66(R) Cell Line, Application to Vaccines, and Therapeutic Protein Production.","volume":"64","author":"Brown S. W.","year":"2010","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"e_1_2_11_60_2","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.12350"},{"key":"e_1_2_11_61_2","unstructured":"Guehenneux F. Moreau K. Magali E. Mehtali M. Duck embryonic derived stem cell lines for the production of viral vaccines. European Patent Application EP1985305 A1 2008."},{"key":"e_1_2_11_62_2","unstructured":"Guehenneux F. Pain B. Production of poxviruses with adherent or non adherent avian cell lines. US Patent 233834 A1 2006."},{"key":"e_1_2_11_63_2","unstructured":"Mehtali M. Champion\u2010Arnaud P. Arnaud L. Production of Viral Vaccines in Suspension on Avian Embryonic Derived Stem Cell Lines. US Patent 081251 A1 2009."},{"key":"e_1_2_11_64_2","unstructured":"Pain B. Guehenneux F. Avian cell lines for the production of useful substances. WO Patent 03076601 A1 2003."},{"key":"e_1_2_11_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.048"},{"key":"e_1_2_11_66_2","doi-asserted-by":"publisher","DOI":"10.3382\/ps.2012-02582"},{"key":"e_1_2_11_67_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06242-11"},{"key":"e_1_2_11_68_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02929-13"},{"key":"e_1_2_11_69_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03839-13"},{"key":"e_1_2_11_70_2","unstructured":"Reiter M. Mundt W. Feigl S. von Fricks S. Method for producing continuous cell linesAU2013206102 A1 2013."},{"key":"e_1_2_11_71_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-8-1987"},{"key":"e_1_2_11_72_2","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.4.1.89"},{"key":"e_1_2_11_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2008.04.004"},{"key":"e_1_2_11_74_2","first-page":"883","article-title":"Cloning of a new fibroblast cell line from an early primary culture from mandarin fish (Siniperca chuatsi) fry for efficient proliferation of megalocytiviruses.","volume":"6","author":"Dong C.","year":"2013","journal-title":"Cytotechnology"},{"key":"e_1_2_11_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-013-1617-7"},{"key":"e_1_2_11_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.418"},{"key":"e_1_2_11_77_2","doi-asserted-by":"publisher","DOI":"10.1006\/fsim.2000.0330"},{"key":"e_1_2_11_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02254991"},{"key":"e_1_2_11_79_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2144\/04372BM02","article-title":"Molecular cytogenetic characterization by combined COBRA\u2010FISH and fiber\u2010FISH: application to PER.C6 cells.","volume":"37","author":"Wiegant J.","year":"2004","journal-title":"Biotechniques"},{"key":"e_1_2_11_80_2","first-page":"205","article-title":"Design of alternative live attenuated influenza virus vaccines.","volume":"386","author":"Finch C.","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"e_1_2_11_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-014-6298-y"},{"key":"e_1_2_11_82_2","doi-asserted-by":"publisher","DOI":"10.1038\/227168a0"},{"key":"e_1_2_11_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4827(65)90211-9"},{"key":"e_1_2_11_84_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82079-0"},{"key":"e_1_2_11_85_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.007"},{"key":"e_1_2_11_86_2","unstructured":"Uytdehaag A. G. C. Pau M. G. Schouten G. Production influenza virus vaccines. WO Patent 045674 A1 2007."},{"key":"e_1_2_11_87_2","unstructured":"Pau M. G. Uytdehaag A. G. C. Schouten G. Production of vaccines. US Patent 0063261 A1 2006."},{"key":"e_1_2_11_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.10.070"},{"key":"e_1_2_11_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.09.055"},{"key":"e_1_2_11_90_2","unstructured":"De Vocht M. L. Backus H. H. J. Van Corven E. J. J. Lagerwerf F. et al. Methods for the production of a whole\u2010inactivated West Nile virus vaccine. WO Patent 122964 A1 2006."},{"key":"e_1_2_11_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.05.083"},{"key":"e_1_2_11_92_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-12-79"},{"key":"e_1_2_11_93_2","unstructured":"Jordan I. Sandig V. Novel MVA virus and uses thereof. WO Patent 048500 A1 2014."},{"key":"e_1_2_11_94_2","unstructured":"Jordan I. Sandig V. Cell line for propagation of highly attenuated alphaviruses US 2011\/0229969 A1 2011."},{"key":"e_1_2_11_95_2","doi-asserted-by":"publisher","DOI":"10.1080\/03079457.2014.939941"}],"container-title":["Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbiot.201400388","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/biot.201400388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:38:46Z","timestamp":1759941526000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/biot.201400388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,22]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1002\/biot.201400388"],"URL":"https:\/\/doi.org\/10.1002\/biot.201400388","archive":["Portico"],"relation":{},"ISSN":["1860-6768","1860-7314"],"issn-type":[{"value":"1860-6768","type":"print"},{"value":"1860-7314","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,22]]}}}